Eliem Therapeutics (ELYM) News Today $2.34 -0.08 (-3.31%) (As of 12/17/2024 ET) Add Compare Share Share Headlines Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Point72 Asset Management L.P. Takes Position in Eliem Therapeutics, Inc. (NASDAQ:ELYM)Point72 Asset Management L.P. purchased a new stake in shares of Eliem Therapeutics, Inc. (NASDAQ:ELYM - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 590,946 shares of the company's stock, vDecember 10, 2024 | marketbeat.comJanus Henderson Group PLC Boosts Stock Holdings in Eliem Therapeutics, Inc. (NASDAQ:ELYM)Janus Henderson Group PLC increased its position in Eliem Therapeutics, Inc. (NASDAQ:ELYM - Free Report) by 10.8% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 3,606,495 shares of the company's stock after acquDecember 8, 2024 | marketbeat.comEliem Therapeutics, Inc. (NASDAQ:ELYM) Shares Sold by Samsara BioCapital LLCSamsara BioCapital LLC trimmed its holdings in shares of Eliem Therapeutics, Inc. (NASDAQ:ELYM - Free Report) by 20.0% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,609,114 shares of the company's stock after seDecember 5, 2024 | marketbeat.com278,775 Shares in Eliem Therapeutics, Inc. (NASDAQ:ELYM) Purchased by Parkman Healthcare Partners LLCParkman Healthcare Partners LLC acquired a new position in Eliem Therapeutics, Inc. (NASDAQ:ELYM - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 278,775 shares of the company's stock, valDecember 4, 2024 | marketbeat.comEliem Therapeutics, Inc. (NASDAQ:ELYM) Shares Purchased by Ally Bridge Group NY LLCAlly Bridge Group NY LLC grew its holdings in shares of Eliem Therapeutics, Inc. (NASDAQ:ELYM - Free Report) by 145.9% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,229,292 shares of the company's sNovember 28, 2024 | marketbeat.comGreat Point Partners LLC Takes Position in Eliem Therapeutics, Inc. (NASDAQ:ELYM)Great Point Partners LLC acquired a new stake in shares of Eliem Therapeutics, Inc. (NASDAQ:ELYM - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 248,168 shares of the company's stock,November 27, 2024 | marketbeat.comEliem Therapeutics (NASDAQ:ELYM) Stock, Short Interest ReportOctober 9, 2024 | benzinga.comEliem Therapeutics Announces Rebranding and Corporate Name Change to Climb Bio, Inc.October 2, 2024 | globenewswire.comEliem Therapeutics, Inc. (NASDAQ:ELYM) Shares Sold by Driehaus Capital Management LLCDriehaus Capital Management LLC lessened its stake in shares of Eliem Therapeutics, Inc. (NASDAQ:ELYM - Free Report) by 14.2% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 696,057 shares of the company's stockSeptember 30, 2024 | marketbeat.comAffinity Asset Advisors LLC Invests $11.88 Million in Eliem Therapeutics, Inc. (NASDAQ:ELYM)Affinity Asset Advisors LLC bought a new stake in Eliem Therapeutics, Inc. (NASDAQ:ELYM - Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 1,670,661 shares of the company's stock, valued at approxiSeptember 25, 2024 | marketbeat.comEliem Therapeutics: Recent Strategic Pipeline RestructuringSeptember 23, 2024 | seekingalpha.comAlly Bridge Group NY LLC Takes $3.56 Million Position in Eliem Therapeutics, Inc. (NASDAQ:ELYM)Ally Bridge Group NY LLC purchased a new stake in Eliem Therapeutics, Inc. (NASDAQ:ELYM - Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 500,000 shares of the company's stock, valued at approximately $3,5September 23, 2024 | marketbeat.comEliem Therapeutics to Participate at the Stifel 2024 Virtual Immunology and Inflammation SummitSeptember 11, 2024 | globenewswire.comEliem Therapeutics (NASDAQ:ELYM) Shares Up 4.6%Eliem Therapeutics (NASDAQ:ELYM) Trading 4.6% HigherSeptember 6, 2024 | marketbeat.comEliem Therapeutics Announces Additions to its Leadership TeamAugust 26, 2024 | globenewswire.comEliem Therapeutics Reports Second Quarter Financial ResultsAugust 14, 2024 | globenewswire.comEliem Therapeutics, Inc. (NASDAQ:ELYM) Short Interest UpdateEliem Therapeutics, Inc. (NASDAQ:ELYM - Get Free Report) was the recipient of a significant increase in short interest during the month of July. As of July 15th, there was short interest totalling 742,200 shares, an increase of 98.8% from the June 30th total of 373,300 shares. Based on an average trading volume of 307,600 shares, the days-to-cover ratio is presently 2.4 days. Approximately 1.3% of the shares of the company are short sold.July 26, 2024 | marketbeat.comEliem Therapeutics, Inc. (NASDAQ:ELYM) EVP Valerie Morisset Sells 69,005 SharesJuly 24, 2024 | insidertrades.comInsider Selling: Eliem Therapeutics, Inc. (NASDAQ:ELYM) EVP Sells 60,201 Shares of StockJuly 24, 2024 | insidertrades.comInsider Sale at Eliem Therapeutics Inc: EVP, R&D AND CSO Valerie Morisset Sells SharesJuly 24, 2024 | finance.yahoo.comIQVIA Posts Upbeat Earnings, Joins Terex, Reddit And Other Big Stocks Moving Higher On MondayJuly 22, 2024 | benzinga.comValerie Morisset Sells 3,207 Shares of Eliem Therapeutics, Inc. (NASDAQ:ELYM) StockJuly 21, 2024 | insidertrades.comInsider Sale at Eliem Therapeutics Inc (ELYM): EVP, R&D AND CSO Valerie Morisset Sells ...July 19, 2024 | sg.finance.yahoo.comEVP, R&D AND CSO Valerie Morisset Sells 50,000 Shares of Eliem Therapeutics Inc (ELYM)July 19, 2024 | finance.yahoo.comValerie Morisset Sells 42,377 Shares of Eliem Therapeutics, Inc. (NASDAQ:ELYM) StockJuly 18, 2024 | insidertrades.comInsider Selling: Eliem Therapeutics, Inc. (NASDAQ:ELYM) EVP Sells 42,377 Shares of StockEliem Therapeutics, Inc. (NASDAQ:ELYM - Get Free Report) EVP Valerie Morisset sold 42,377 shares of the firm's stock in a transaction on Monday, July 15th. The shares were sold at an average price of $7.01, for a total value of $297,062.77. Following the completion of the sale, the executive vice president now owns 252,306 shares of the company's stock, valued at $1,768,665.06. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.July 16, 2024 | marketbeat.comInsider Selling: Eliem Therapeutics, Inc. (NASDAQ:ELYM) EVP Sells 5,931 Shares of StockJuly 12, 2024 | insidertrades.comInsider Selling: Eliem Therapeutics, Inc. (NASDAQ:ELYM) EVP Sells 50,000 Shares of StockJuly 12, 2024 | insidertrades.comEliem Therapeutics, Inc. (NASDAQ:ELYM) Sees Significant Growth in Short InterestEliem Therapeutics, Inc. (NASDAQ:ELYM - Get Free Report) was the recipient of a large increase in short interest in the month of June. As of June 30th, there was short interest totalling 373,300 shares, an increase of 552.6% from the June 15th total of 57,200 shares. Currently, 0.8% of the shares of the company are sold short. Based on an average trading volume of 918,600 shares, the days-to-cover ratio is presently 0.4 days.July 11, 2024 | marketbeat.comInsider Selling: Eliem Therapeutics, Inc. (NASDAQ:ELYM) EVP Sells 12,342 Shares of StockJuly 10, 2024 | insidertrades.comEliem Therapeutics, Inc. (NASDAQ:ELYM) EVP Valerie Morisset Sells 50,000 SharesJuly 4, 2024 | insidertrades.comRa Capital Management, L.P. Acquires 13,008,546 Shares of Eliem Therapeutics, Inc. (NASDAQ:ELYM) StockJuly 2, 2024 | insidertrades.comEliem Therapeutics, Inc. (NASDAQ:ELYM) Director Buys $49,952,816.64 in StockEliem Therapeutics, Inc. (NASDAQ:ELYM - Get Free Report) Director Ra Capital Management, L.P. acquired 13,008,546 shares of Eliem Therapeutics stock in a transaction on Thursday, June 27th. The shares were bought at an average price of $3.84 per share, for a total transaction of $49,952,816.64. Following the completion of the purchase, the director now directly owns 23,521,757 shares in the company, valued at $90,323,546.88. The purchase was disclosed in a legal filing with the SEC, which is available through this link.July 1, 2024 | marketbeat.comEliem Therapeutics Announces its Addition to the Russell 2000® and Russell 3000® IndexesJune 28, 2024 | globenewswire.comEliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private PlacementJune 27, 2024 | globenewswire.comEliem Therapeutics, Inc. (NASDAQ:ELYM) Short Interest Down 53.5% in MayEliem Therapeutics, Inc. (NASDAQ:ELYM - Get Free Report) was the target of a significant decline in short interest during the month of May. As of May 31st, there was short interest totalling 59,900 shares, a decline of 53.5% from the May 15th total of 128,800 shares. Based on an average daily trading volume, of 863,600 shares, the days-to-cover ratio is currently 0.1 days. Currently, 0.3% of the shares of the company are sold short.June 13, 2024 | marketbeat.comShort Interest in Eliem Therapeutics, Inc. (NASDAQ:ELYM) Rises By 127.2%Eliem Therapeutics, Inc. (NASDAQ:ELYM - Get Free Report) saw a significant growth in short interest in the month of May. As of May 15th, there was short interest totalling 128,800 shares, a growth of 127.2% from the April 30th total of 56,700 shares. Based on an average trading volume of 850,300 shares, the short-interest ratio is presently 0.2 days. Approximately 0.7% of the shares of the company are sold short.May 29, 2024 | marketbeat.comEliem Therapeutics Stock (NASDAQ:ELYM), Earnings Estimates, EPS, and RevenueMay 17, 2024 | benzinga.comShort Interest in Eliem Therapeutics, Inc. (NASDAQ:ELYM) Increases By 4,453.8%Eliem Therapeutics, Inc. (NASDAQ:ELYM - Get Free Report) was the target of a large increase in short interest during the month of April. As of April 15th, there was short interest totalling 601,100 shares, an increase of 4,453.8% from the March 31st total of 13,200 shares. Currently, 3.3% of the company's stock are short sold. Based on an average trading volume of 665,800 shares, the short-interest ratio is currently 0.9 days.April 25, 2024 | marketbeat.comBML Capital Management LLC Boosts Holdings in Eliem Therapeutics, Inc. (NASDAQ:ELYM)BML Capital Management LLC boosted its position in shares of Eliem Therapeutics, Inc. (NASDAQ:ELYM - Free Report) by 12.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,180,000 shares of the compApril 24, 2024 | marketbeat.comEliem Therapeutics (NASDAQ:ELYM) Trading 0.5% Higher Eliem Therapeutics (NASDAQ:ELYM) Shares Up 0.5%April 23, 2024 | marketbeat.comSHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Eliem Therapeutics, Inc. (ELYM) and Encourages Investors to Contact the FirmApril 15, 2024 | prnewswire.comEliem Therapeutics, Inc.: Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private PlacementApril 12, 2024 | finanznachrichten.deSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALPN, ELYM, MODNApril 11, 2024 | stockhouse.comEliem Therapeutics Shifts From Neurology With New Found Focus On Autoimmune Diseases With Tenet Medicines DealApril 11, 2024 | finance.yahoo.comEnlivex Therapeutics, Nyxoah SA, China SXT Pharmaceuticals among healthcare moversApril 11, 2024 | msn.comEliem Therapeutics To Buy Tenet Medicines, Plans $120 Mln Private Placement; Stock Up In Pre-marketApril 11, 2024 | markets.businessinsider.comELYM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Eliem Therapeutics, Inc. Is Fair to ShareholdersApril 11, 2024 | businesswire.comEliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private PlacementApril 11, 2024 | globenewswire.comELYM Stock Earnings: Eliem Therapeutics Reported Results for Q4 2023April 5, 2024 | msn.com Get Eliem Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ELYM and its competitors with MarketBeat's FREE daily newsletter. Email Address How this >10-cent coin is going to outperform Bitcoin (Ad)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 different coins that have returned over 100%... But today, Chris is now making the biggest crypto call of his ENTIRE career… #1 FREE Crypto for 2024 ELYM Media Mentions By Week ELYM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ELYM News Sentiment▼1.830.72▲Average Medical News Sentiment ELYM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ELYM Articles This Week▼01▲ELYM Articles Average Week Get Eliem Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ELYM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Immutep News 4D Molecular Therapeutics News C4 Therapeutics News Larimar Therapeutics News Benitec Biopharma News COMPASS Pathways News Foghorn Therapeutics News AC Immune News Amylyx Pharmaceuticals News Lifecore Biomedical News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ELYM) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | SponsoredMissed Nvidia? Buy Elon Musk’s “Silent Partner”In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my f...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eliem Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eliem Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ELYM Stock Alerts